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Abstract
The cancer microenvironment plays a pivotal role in oncogenesis, containing a number of regulatory cells that attenuate the
anti-neoplastic immune response. While the negative prognostic impact of regulatory T cells (Tregs) in the context of most
solid tissue tumors is well established, their role in lymphoid malignancies remains unclear. T cells expressing FOXP3 and
Helios were documented in the fine needle aspirates of affected lymph nodes of dogs with spontaneous multicentric B cell
lymphoma (BCL), proposed to be a model for human non-Hodgkin lymphoma. Multivariable analysis revealed that the
frequency of lymph node FOXP3+ T cells was an independent negative prognostic factor, impacting both progression-free
survival (hazard ratio 1.10; p = 0.01) and overall survival (hazard ratio 1.61; p = 0.01) when comparing dogs showing higher
than the median FOXP3 expression with those showing the median value of FOXP3 expression or less. Taken together,
these data suggest the existence of a population of Tregs operational in canine multicentric BCL that resembles thymic
Tregs, which we speculate are co-opted by the tumor from the periphery. We suggest that canine multicentric BCL
represents a robust large animal model of human diffuse large BCL, showing clinical, cytological and immunophenotypic
similarities with the disease in man, allowing comparative studies of immunoregulatory mechanisms.
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Introduction
Non-Hodgkin lymphoma (NHL), a heterogeneous group of
lymphoid malignancies [1,2], is the eleventh most common cause
of death from cancer in humans worldwide, estimated to be
responsible for approximately 192,000 deaths in 2008 alone [3].
Despite advances in therapy in recent years, five-year survival rates
are as low as 25% for the more aggressive subtypes of NHL [3].
There is thus an urgent need to develop novel, targeted therapies
for this group of diseases, driven by advances in our understanding
of their pathogenesis and specific prognosis. Current rodent
models of lymphoma are far from predictive of the natural course
of the human disease, relying either on the subcutaneous
implantation of xenogeneic lymphoma cells into immune-com-
promised mice, or on genetic manipulations that artificially
increase the likelihood of lymphoma in a monogenic fashion [4].
Key to advancing the field will be the development of natural,
polygenic animal models of NHL, allowing the further interroga-
tion of molecular and cellular pathogenesis, as well as trials of
novel anti-cancer agents. The dog has gained traction in recent
years as a model for a number of human diseases, including
various malignancies [5–8]. Its spontaneous development of
mesenchymal, epithelial and round cell tumors, relatively short
lifespan, and cohabitation of our environment, as well as the
availability of advanced diagnostic and therapeutic modalities that
are similar to those available in human oncology clinics, all make
this species attractive as a model for cancer research [7,9,10].
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Furthermore, the most prevalent subtype of canine lymphoma,
diffuse large (DL) BCL, mirrors the most common form of NHL
[11], and various studies suggest that the molecular pathogenesis
of DLBCL in the two species is fundamentally similar [12–15].
One of the key pathogenic determinants in oncogenesis is the
cancer microenvironment [16–20]. Interactions with stromal and
immune cells and extracellular matrix components conspire to
inhibit anti-neoplastic immune responses, allowing the cancer to
grow and metastasize. Central among such cellular interactions
are those occurring with Tregs, of which the thymic subset is
generally identified by its expression of the Forkhead box
transcription factor FOXP3 in addition to the classical markers
CD4 and CD25high [21]. While the negative prognostic impact of
FOXP3+ Tregs in various solid tumors of both mesenchymal and
epithelial origin has been well documented [22,23], these cells
have also been associated with a favorable outcome in certain solid
tumors [24,25] and their role in the pathogenesis of lymphoid
malignancies is much less clear [26]. Some papers suggest that
intra-tumoral Tregs predict a negative outcome in human
lymphoma [27–31], while others suggest that they may have a
beneficial effect [32–40]; yet others propose that they have neither
a positive nor a negative prognostic impact [41]. The situation is
further complicated by the presence of more than one subset of
Treg – including both thymic and peripheral IL-10-secreting (Tr1)
phenotypes – and interactions with other cells with suppressive
properties, including myeloid-derived suppressor cells, natural
killer T (NKT) cells and tolerogenic dendritic cells [42–45].
While a number of recent studies have added weight to the
suggestion that lymphoma in the dog closely resembles human
NHL [12–15], very little is known about the role of Tregs in
canine BCL. We and others have recently characterised FOXP3+
Tregs in the dog [46], demonstrating that they have similar
properties to those of human Tregs; we were thus optimally poised
to interrogate their role in various canine diseases, including
lymphoma. The aim of the present study was therefore to
document the presence of FOXP3+ Tregs in the resident T cell
population of affected lymph nodes of dogs with B cell lymphoma
(BCL) and to test the hypothesis that intra-tumoral CD4+FOXP3+
Tregs have a negative impact on treatment outcome, making
comparisons with dogs with T cell lymphoma (TCL), non-
neoplastic causes of lymphadenomegaly, and metastatic mast cell
tumors (MCTs). Our goal was to advance our understanding of
the pathogenesis of canine BCL, thus further validating this
spontaneous, naturally occurring disease as a large animal model
of NHL in which to study the role of immunoregulatory pathways.
Materials and Methods
Case accession
Dogs were recruited to this study from four different veterinary
practices, three located in the UK and one in Sweden. Complete
clinical histories were obtained from every dog. Diagnostic
investigations appropriate to the presenting complaints were
undertaken in all dogs, including cytological and, or histopatho-
logical review of enlarged lymph nodes by a board-certified
veterinary pathologist. Standard clinical staging was undertaken
by means of thoracic radiographs or computed tomography;
abdominal ultrasound examination; fine needle aspirates (FNAs) of
the liver and spleen when sonographic lesions of these organs were
identified; and bone marrow aspirates when prompted by
peripheral cytopenias. Stages IV and V were thus assigned with
the caveat that aspirates of the liver, spleen and bone marrow were
not undertaken in every dog. Study samples comprised blood
collected by venepuncture of a peripheral vein into EDTA and
serum gel tubes, and three to four fine needle aspirates (FNAs) of a
representative, enlarged lymph node deposited into neat fetal
bovine serum (PAA Laboratories Ltd, Yeovil, UK) for flow
cytometry. Staining of cells for flow cytometry was performed
within 48 hours of sample collection, followed by acquisition of the
fixed cells within a further 72 hours. (Pilot studies had established
that the immunophenotype of samples remained stable up to
48 hours after sample collection.) Serum was harvested within two
hours of sample collection and was stored at a temperature of 2
20uC until analysis.
Twenty-two of the dogs recruited were diagnosed with BCL,
whilst the remaining cases were recruited to three different control
groups. The first comprised 14 dogs with TCL; the second
comprised 14 dogs with reactive hyperplasia (RH) associated with
cutaneous inflammation/dermatitis, immune-mediated disease,
distant neoplasia (i.e. non-draining lymph nodes were sampled)
or systemic infection; while the third comprised six dogs with
metastatic MCTs, the samples in these cases having been collected
from draining lymph nodes. Flow cytometric analyses of periph-
eral blood were undertaken in these dogs and a group of 25
healthy control (HC) dogs, which also contributed serum samples.
(C-reactive protein and cytokine assays, reported elsewhere, were
undertaken on all of the serum samples.) For ethical and legal
reasons, lymph node samples could not be obtained from HC
dogs. All patient samples were collected by licensed veterinarians
in routine diagnostic fashion following written informed consent
and all study protocols were approved by the Royal Veterinary
College Ethics and Welfare Committee (Permit Number: URN-
20101005). None of the dogs suffered any adverse consequences of
sample procurement.
Cytomorphological classification
When available, slides of diagnostic specimens were retrieved
from the receiving diagnostic laboratories for review by a board-
certified clinical pathologist involved in the study (BS) for
cytomorphological classification. Cytological features that were
recorded in the study are presented in Table S1. Based on these
observations and the immunophenotype of the lymphoma, the
most likely subtype was deduced – for example, DLBCL – though
histopathological review would have been required to confirm
such tissue diagnoses.
Flow cytometry
A panel of canine-specific or cross-reactive fluorochrome-
conjugated monoclonal antibodies (mAbs) against both extra-
and intra-cellular antigens was applied (Table 1). The manufac-
turer’s protocol for FOXP3 staining was applied. Briefly,
lymphocytes were washed and stained with mAbs for 20 minutes
on ice. Lymphocytes were then washed and incubated overnight in
a 1:4 (concentrate:diluent) fixation/permeabilization solution.
Following incubation, the lymphocytes were washed twice and
then stained with mAbs against intracellular antigens for 30
minutes on ice. All incubations were carried out in the dark. Upon
completion, lymphocytes were washed twice and re-suspended in
200 ml phosphate buffered saline (PBS) solution. Isotype control
antibodies were used to define gates in all experiments. Three-
colour staining was used throughout the study, T cells identified in
a panel comprising mAbs against CD5 and FOXP3 with CD4,
CD8 or Helios. Data were acquired using a FACS Canto II flow
cytometer (BD Biosciences) and were analyzed using Flowjo (Tree
Star Inc) software.
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Immunophenotypic determination
A threshold of 60% marker expression was used to classify
patient samples as being of either a B or T cell phenotype,
adopting a previously validated diagnostic protocol [47]. This
threshold was applied to the 30% of largest events following
removal of dead cells and debris by appropriate gating, as
determined by forward and side scatter characteristics (Figure 1).
Where at least 60% of cells expressed CD21 or CD79b, a
classification of BCL was made. Conversely, when at least 60% of
cells expressed CD5, CD4 or CD8 a classification of TCL was
made. To further interrogate the composition of cell populations
in FNAs, an ‘All’ gate was applied, which again excluded dead
events. Non-neoplastic and neoplastic populations of cells within
the BCL FNAs were then evaluated on the basis of CD5
expression, which was limited to the resident (non-neoplastic) T
cells in the majority of such cases. An equivalent strategy was
applied to both the RH and MCT groups; however, TCL samples
were excluded from this analysis owing to CD5 expression by both
neoplastic and non-neoplastic cells, which precluded distinction of
the two populations within the aspirated cells. In all cases, the
expression of CD34 in peripheral blood was negligible, ruling out
leukemia.
Clinical definitions and statistical analysis
The following outcome metrics were derived from patient
records and communications with the clinicians involved in this
study: time to remission (TTR), progression-free survival (PFS) and
overall survival (OS). These parameters were determined following
assessment of the response to therapy using Veterinary Cooper-
ative Oncology Group-approved definitions of complete response
(CR), partial response (PR), stable disease (SD) and progressive
disease (PD) applied to peripheral lymph nodes measured by the
attending clinicians [48].
Comparisons between two groups of continuous data were
undertaken using Mann-Whitney U tests and for three or more
groups using Kruskal-Wallis tests. Summary data are presented in
the text in the following format: median, range [lowest to highest
value], number of cases or experimental repeats (n); p value.
Summary data are presented in the form of box plots, in which the
boxes show the respective 25th and 75th percentiles, the horizontal
lines median values, and the whiskers, the lowest and highest data
points still within 1.5 times the interquartile range of the respective
lower and upper quartiles. Dots represent the data from individual
dogs. Red symbols correspond to data from dogs ‘pre-treated’ with
corticosteroids or any chemotherapeutic drug within three weeks
of sampling. In the case of RH cases, square symbols represent
data from dogs with dermatitis; diamonds represent data from dogs
with distant neoplasia; triangles represent data from dogs with
immune-mediated disease; and inverted triangles represent data
from dogs with systemic infection.
Survival analysis of the dogs with lymphoma was performed
using Cox’s proportional hazards regression and presented in the
form of Kaplan-Meier curves. Continuous variables were catego-
rised to produce the Kaplan-Meier curves using the median value
as a threshold. Both univariable and multivariable analyses were
undertaken. Criteria for inclusion of variables into the multivar-
iable model included significance at the level of univariable
analysis, lack of overlap of the respective survival curves, and
constancy of the risk (hazard) with time. Only the BCL cases were
analyzed as a separate group for the prognostic impact of
phenotypic variables; there were too few TCL cases to make
survival analysis of phenotypic variables of this group meaningful.
Dogs that failed to go into complete remission were censored for
TTR analysis; those that did not show progression, including
death, at the last known follow-up time point were censored for
PFS analysis; and those that were still alive at the last known
follow-up time point were censored for OS analysis. Rescue
therapy was not a criterion for censorship in the OS analysis.
Results
Clinical and immunophenotypic details of cases and
controls
A total of 22 BCL, 14 TCL, 14 RH, six MCT and 25 HC dogs
were recruited into the study. A summary of the signalment and
clinical details of the BCL, TCL, RH, MCT and HC cases is
presented in Table 2; further details are presented in Tables S2 to
S5.
Comparing the BCL, TCL, RH and MCT dogs, there was no
significant difference in age (p = 0.51), sex (p = 0.14), neutering
status (p = 0.27), bodyweight (p = 0.09) or body condition
(p = 0.86) between the groups. The BCL dogs tended to be of
higher stage (III 41%, IV 32%, V 27%) than the TCL (II 7%, III
79%, IV 14%; p = 0.02), but there was no difference in sub-stage
between the groups (p = 1.00). In common with the prevailing
literature, TCL dogs were more commonly hypercalcemic (4/13;
31%) than BCL (1/22, 4.5%; p = 0.05). Among the lymphoma
dogs, the cytomorphological characteristics when considered
alongside immunophenotype were most commonly consistent
with DLBCL (11/22; 50%) and peripheral TCL (8/14, 57%;
Table 2, Figure S1). The most common chemotherapy protocol in
both BCL and TCL dogs was CHOP, comprising cyclophospha-
Table 1. Staining antibodies, isotype controls and fluorochromes.
Antigen Clone Isotype Fluorochrome Supplier
CD5 YKIX322.3 Rat IgG2a FITC/PE AbD Serotec, UK
CD4 YKIX302.9 Rat IgG2a FITC/PE AbD Serotec, UK
CD8 YCATE55.9 Rat IgG1 FITC/PE AbD Serotec, UK
CD79b AT107-2 Rat IgG1 FITC AbD Serotec, UK
CD21 CA2.1D6 Mouse IgG1 PE AbD Serotec, UK
CD34 1H6 Mouse IgG1 PE AbD Serotec, UK
FOXP3 FJK-16s Rat IgG2a APC eBioscience, UK
Helios 22F6 Armenian hamster IgG PE Biolegend, UK
Abbreviations: FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.
doi:10.1371/journal.pone.0105027.t001
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mide, doxorubicin, vincristine and prednisolone (Tables 1, S2 and
S3).
Treatment of the BCL and TCL dogs with a corticosteroid or
any cytotoxic chemotherapeutic drugs within three weeks of
sampling was considered a confounding factor, since such drugs
may theoretically alter the frequency of peripheral Tregs. Of the
BCL cases, 9/21 (43%) dogs had been ‘pre-treated’ in this way,
compared to 5/13 (38%) of the TCL cases. (In each respective
BCL and TCL group, one dog received no treatment at all.)
Phenotypic characteristics of the pre-treated dogs were no different
from those that had not received such drugs prior to sampling
(BCL, p.0.05; TCL, p.0.05) and pre-treatment had no impact
on outcome variables (TTR: BCL, p = 0.58; TCL, p = 0.46; PFS:
BCL, p = 0.30; TCL, p = 0.11; OS: BCL, p = 0.28; TCL,
p = 0.91). The pre-treated and treatment-naı¨ve groups were
therefore considered as a single group in respective BCL and
TCL cases. A complete response to chemotherapy was achieved in
17/21 (81%) of the BCL cases and in 8/13 (62%) of the TCL
cases. Thus, four of the BCL and five of the TCL dogs were
censored from TTR analysis. One dog in each lymphoma group
was censored from PFS analysis, while five BCL and two TCL
dogs were censored from OS analysis. Comparing the BCL with
TCL groups, there was no difference in TTR (BCL: median 20
days versus TCL: median 27 days; p = 0.09), PFS (BCL: median
117 days versus TCL: median 63 days; p = 0.47) or OS (BCL:
median 294 days versus TCL: median 151 days; p = 0.21). In the
case of the BCL group, older dogs had shorter PFS (median 74
days) than younger dogs (median 174 days; p = 0.006) and dogs
treated with CHOP had longer PFS (median 175 days) than those
treated with the other protocols (median 45 days; p = 0.01) (Figure
S2). Rescue therapy, which was unstandardized, was administered
to 10 of the BCL dogs and nine of the TCL dogs (Tables S2 and
S3). In the case of both the BCL and TCL groups, dogs receiving
rescue therapy had longer OS than those not receiving it (BCL:
median OS 322 days versus 174 days respectively, p = 0.049;
TCL: median OS 230 days versus 9.5 days respectively, p = 0.008;
combined BCL+TCL: 294 days versus 102 days respectively,
p = 0.013). There was no association with prognosis in either the
BCL or the TCL groups for sex, neutering status, body weight,
body condition, stage, substage or presence of hypercalcemia (in
all cases p.0.05).
Neoplastic effacement of normal lymphoid tissue
impacts FOXP3, Helios and CD8 expression, but the ratio
of cytotoxic to regulatory T cells is not decreased in
canine B cell lymphoma
The median frequency of FOXP3+ cells within the whole
population of cells harvested by fine needle aspiration, identified
by the ‘All’ gate, was significantly lower in BCL (1.1% [0.16%–
Figure 1. Gating strategies used to interrogate the neoplastic and non-neoplastic cell populations. Following exclusion of dead cells
and debris, two different gating strategies were employed to evaluate the cells isolated from lymph node aspirates. For the purposes of generating
an immunophenotyping profile, an upper 30% gate was applied to identify the population of largest events, enriched in neoplastic cells. The
immunophenotype was then determined using a 60% expression threshold within this population. For the purposes of evaluating frequencies of T
cells within fine needle aspirates of B cell lymphoma (BCL), reactive hyperplasia (RH) and mast cell tumour (MCT) cases, an ‘All’ gate was applied and
then the populations subsequently delineated by means of CD5 expression. Non-neoplastic cells were identified as CD5+ and neoplastic populations
CD52 in the context of BCL; TCL cases were excluded from such comparisons on account of their CD5 expression by both neoplastic and non-
neoplastic cells.
doi:10.1371/journal.pone.0105027.g001
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Table 2. Clinical, cytological and treatment details of dogs in the study.
B cell lymphoma T cell lymphoma Reactive hyperplasia Mast cell tumor Healthy control dogs
Age (months)1 Median (range) 113 (33–171) 93 (58–163) 108 (15–156) 138 (84–176) 55 (19–324)
Sex Me 6 4 1 0 2
Mn 7 3 6 0 11
Fe 4 1 1 1 2
Fn 5 6 6 5 10
Breed Labrador retriever
(n = 2); Afghan
hound, Australian
silky, Bernese
mountain dog,
Border collie,
bullmastiff, cocker
spaniel, Doberman,
English springer
spaniel, flat-coated
retriever, German
shepherd dog,
golden retriever,
Jack Russell terrier,
Shar pei, Shetland
sheepdog, shih tzu,
spaniel cross,
Staffordshire bull
terrier, Tibetan terrier,
undefined cross breed,
West Highland white
terrier (all n = 1)
Boxer (n = 4);
Labrador
retriever (n = 3);
cocker spaniel
(n = 2); Border
collie, Dogue de
Bordeaux, English
springer spaniel,
golden retriever,
Shetland
sheepdog
(all n = 1)
Fox terrier (n = 2);
Labrador retriever
(n = 2); Border collie,
cocker spaniel, French
bulldog, German
shepherd dog, Irish
terrier, Jack Russell
terrier, Labrador cross,
Patterdale terrier,
Rottweiler, undefined
cross breed (all n = 1)
Golden retriever
(n = 2); Labrador
retriever (n = 2);
Rottweiler,
undefined cross
breed (all n = 1)
Rhodesian ridgeback (n = 3);
Border terrier (n = 2); Jack
Russell terrier (n = 2); Labrador
retriever (n = 2); whippet
(n = 2); greyhound, lurcher,
standard poodle, boxer cross,
Dogue de Bordeaux,
Hungarian vizsla, English
springer spaniel, Japanese
akita, Labrador/English
springer spaniel cross,
Staffordshire bull terrier (all
n = 1); undefined cross breed
(n = 4)
Body condition2 Under 4 1 2 0 0
Optimal 13 9 10 4 24
Over 5 4 2 2 1
WHO stage II 0 1 N/A N/A N/A
III 9 11 N/A N/A N/A
IV 7 2 N/A N/A N/A
V 6 0 N/A N/A N/A
Sub-stage a 11 6 N/A N/A N/A
b 11 8 N/A N/A N/A
Hyper-calcemic?3 No 21 9 N/A N/A N/A
Yes 1 4 N/A N/A N/A
Cytological
appearance
DLBCL: n = 11;
DLBCL or
Burkitt-type: n = 2;
Undefined: n = 1;
Slides not available
for review: n = 8
PTCL: n = 8; Small
cell: n = 1; T zone:
n = 1; Undefined:
n = 1; Slides not
available for
review: n = 3
Reactive lymphoid
hyperplasia
confirmed in every
case
Metastatic mast cell
tumor confirmed in
every case
N/A
Chemotherapy
protocol4
CHOP 14 8 Various drugs
administered, including
antimicrobials, NSAIDs
and prednisolone
Various drugs
administered,
including vinblastine,
prednisolone,
lomustine, masitinib
and toceranib
N/A
COP 3 1 N/A N/A N/A
Other 3 4 N/A N/A N/A
Pred 1 0 N/A N/A N/A
None 1 1 N/A N/A N/A
Abbreviations: Me, entire male; Mn, neutered male; Fe, entire female; Fn, neutered female; WHO, World Health Organization; N/A, not applicable; DLBCL, diffuse large B
cell lymphoma; PTCL, peripheral T cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone protocol; COP, cyclophosphamide, vincristine,
prednisolone protocol; Pred, prednisolone alone; NSAIDS, non-steroidal anti-inflammatory drugs.
Notes: 1: Age when presenting signs were first observed. 2: Body condition score was assessed by different clinicians on either a 5 or 9 point scale: ‘under-conditioned’
was defined by a score of 1–2/5 or 1–3/9; ‘optimal’ was defined by a score of 2.5–3/5 or 4–5/9; while ‘over-conditioned’ was defined by a score of 3.5–5/5 or 6–9/9. 3:
Serum or plasma calcium concentration was not measured in one of the T cell lymphoma cases prior to initiation of therapy. 4: The initial treatment protocol is listed.
‘Other’ treatments included cytarabine, L-asparaginase and lomustine (B cell lymphoma) and L-asparaginase, lomustine, prednisolone, masitinib and chlorambucil (T cell
lymphoma).
doi:10.1371/journal.pone.0105027.t002
Regulatory T Cells in Canine B Cell Lymphoma
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e105027
6.01%]; n = 22) and TCL (0.86% [0.01%–5.15%]; n = 14) cases
than in both RH (6.06% [0.93%–9.50%]; n = 13) and MCT
(5.36% [2.52%–9.57%]; n = 4) cases (p = 0.00005; Figure 2A,B).
This was attributed to effacement and thus ‘dilution’ of normal
lymphoid tissue by tumor cells, prompting further examination of
FOXP3 expression specifically within the T cell population of
BCL, RH and MCT cases. A similarly defined sub-population of
non-neoplastic cells could not be delineated in TCLs owing to
CD5 expression by the neoplastic cells themselves, precluding such
analysis in the TCL cases.
A variable pattern of FOXP3 expression was observed in BCL
lymph node aspirates, but there was no overall difference between
groups when FOXP3 was examined in either the CD5+
population (BCL: 8.56% [0.77%–18.1%], n = 22; RH: 10.8%
[0.37%–18.1%], n = 14; MCT: 9.43% [0.96%–11.7%], n = 4;
p = 0.41) or the specific CD4+CD5+ T cells (BCL: 6.21% [0.57%–
17.1%], n = 22; RH: 6.79% [0.38%–13.4%], n = 14; MCT:
9.51% [5.64%–10.6%], n = 4; p = 0.74) within the lymph nodes
(Figure 2C,D). Furthermore, there was no overall difference in
expression of FOXP3 by PBMCs between groups (BCL: 0.57%
[0.05%–5.07%], n = 10; TCL: 0.31% [0.05%–1.96%], n = 9; RH:
0.67% [0.07%–6.67%], n = 5; MCT: 12.04%, n = 1; p = 0.21)
(Figure 2E). A similar lack of difference in FOXP3 expression
between groups was also apparent when its expression within the
CD5+ (BCL: 2.03% [0.25%–9.91%], n = 11; TCL: 4.31%
[0.18%–6.48%], n = 8; RH: 4.74% [2.43%–10.30%], n = 6;
MCT: 5.9%, n = 1; p = 0.53) or specific CD4+CD5+ T cell
fractions of PBMCs was examined (BCL: 5.29% [0.21%–13.85%],
n = 10; TCL: 5.41% [0.258%–16.02%], n = 9; RH: 8.36%
[5.23%–10.96%], n = 6; MCT: 16.13%, n = 1; p = 0.15) (Figur-
e 2F,G).
The median frequency of expression of Helios within the whole
population of aspirated cells was markedly higher in TCL cases
(33.1% [0.6%–94.0%]; n = 13) than in the other three groups of
dogs (BCL: 3.0% [0.1%–52.3%], n = 22; RH: 6.65% [0.60%–
8.90%], n = 12; MCT: 6.38% [0.50%–9.13%], n = 5;
p = 0.00003), compatible with neoplastic T cell Helios expression
rather than localization of Helios to the thymic Tregs alone
(Figure 3A,B).
Expression of Helios was therefore of limited use in the
identification of thymic Tregs in TCL.
The median frequency of CD8+ cells within the whole
population of harvested cells was significantly lower in the BCL
cases (2.68% [0.89%–10.7%]; n = 20) than in RH cases (11.1%
[1.17%–17.1%], n = 20; p = 0.0005), again attributed to efface-
ment of the normal lymphoid population by neoplastic cells
(Figure 4A,B). In the case of this marker, median expression was
also low in the MCT cases (2.24% [0.82%–6.9%]; n = 4). The
median expression of CD8 specifically by T cells was also lower in
the neoplastic groups than in the RH group (BCL: 11.3% [0.57%–
30.4%], n = 20; MCT: 7.06% [5.35%–9.76%], n = 3; RH: 18.4%
[0.6%–37.1%], n = 11; p = 0.04) (Figure 4C). Rationalizing that
the balance of cytotoxic to regulatory T cells may be perturbed in
BCL, we then examined the ratio of CD8+ to FOXP3+ T cells
within the whole population of harvested cells. Rather than being
lower in BCL cases, the median CD8+:FOXP3+ ratio showed a
trend towards being higher in this group of dogs when compared
to RH (or MCT) cases (BCL: 2.09 [0–27.7], n = 22; RH: 1.63 [0–
5.89], n = 13; MCT: 0.35 [0–1.07]; n = 4; p = 0.06), which became
significant when thymic Tregs were specifically examined by
means of co-expression of FOXP3 and Helios within the overall
population (BCL: 15.6 [2.11–36.1], n = 11; RH: 4.26 [0–12.0],
n = 13; p = 0.04) (Figure 4D,E).
FOXP3, Helios and MHC class II expression all have
prognostic significance in canine B cell lymphoma
The impact of FOXP3, Helios and MHC class II expression on
BCL prognosis was then interrogated using both univariable and
multivariable analysis. FOXP3 expression was a negative prog-
nostic factor in the context of OS and PFS. Patients with total
FOXP3 expression less than or equal to the median value (1.23%)
survived longer than those with expression above the median value
(#1.23%, median OS = 322 days, .1.23%, median OS = 169
days; median ratio 0.52; p = 0.018) (Figure 5A). A similar
phenomenon was observed for PFS: patients with lower FOXP3
expression in the CD5+CD4+ population had a longer PFS than
those with higher FOXP3 expression (#10.2%, median PFS = 211
days, .10.2%, median PFS = 61 days; median ratio 0.29;
p = 0.012) (Figure 5B). The proportional expression of Helios
was also a negative prognostic factor, as patients with expression
lower than the median value had longer PFS (#3.00%, median
PFS = 175 days, .3.00%, median PFS = 62 days; median ratio
0.35; p = 0.014) (Figure 5C). The intensity of MHC class II
expression by the lymphoma cells, expressed as the ratio of
geometric mean fluorescence intensity of MHC II+:MHC II2 cells
within the CD52 subset of the ‘All’ gate, was also of prognostic
significance (Figure 5D): TTR was longer in those cases with
expression ratios less than or equal to the median value (#4.40,
median 22 days, .4.40, median 10 days; p = 0.017).
Multivariable analysis yielded two independent factors impact-
ing PFS, age and frequency of FOXP3 expression by lymph node
CD5+CD4+ T cells, and two independent factors impacting OS,
the administration of rescue therapy and the frequency of FOXP3
expression within the total harvested population (Table 3). In the
case of OS analysis, a similar proportion of dogs in the FOXP3low
(#1.23%: 6/11) and FOXP3high (.1.23%: 4/10) group had
received rescue therapy (p = 0.67). Univariable analysis identified
only a single factor impacting TTR (MHC class II expression),
obviating the need for multivariable analysis for this outcome
variable.
Discussion
To the authors’ knowledge, this study represents the first
attempt to define the prognostic impact of Tregs in a well-
characterized cohort of canine cases of multicentric BCL. Despite
the relatively small size of the cohort and heterogeneity of
treatment protocols, the expression of FOXP3 emerged as an
independent prognostic factor, alongside the expression of MHC
class II, age at presentation and the administration of rescue
therapy. This observation raises the intriguing possibility that the
dog, in common with other species, harbors thymic Tregs within
the neoplastic microenvironment of BCL, which are likely to
interact with the neoplastic B cells, stromal cells, and other
regulatory populations such as tolerogenic dendritic cells, tumor-
associated macrophages, myeloid-derived suppressor cells and cd
T cells.
Control dogs included those with TCL, non-neoplastic
lymphadenomegaly (RH) and metastatic MCTs, the latter as an
example of an alternative round cell tumor. In common with
previous literature, boxers appeared to be over-represented in the
TCL group (4/14, 29%) [49–52] and dogs with TCL were more
commonly hypercalcemic than those with BCL [53,54]. Cytolog-
ical reviews were possible in 14 of 22 BCL and 11 of 14 TCL
cases, suggesting a predominance of DLBCL and peripheral TCL.
This observation accords with both previous veterinary literature,
in which these cytological classifications were the most commonly
recognized among multicentric BCL and TCL cases [51,55,56],
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Figure 2. FOXP3+ Treg frequency is no higher in canine B cell lymphoma than control samples. The frequency of FOXP3+ cells in fine
needle aspirates harvested from the lymph nodes of dogs with B cell lymphoma (BCL), T cell lymphoma (TCL), reactive hyperplasia (RH) and mast cell
tumors (MCT) is shown, expressed as a proportion of all cells (A, B, showing the effect of neoplastic effacement of normal lymphoid tissue;
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and reviews of human NHL [2,57]. The similar cytological
appearance of the most common types of canine and human BCL
adds weight to the notion that the canine disease could model
NHL [11]. However, although FNAs are still the cornerstone of
lymphoma diagnosis in canine patients and serve an important
triaging role in people with lymphadenomegaly by virtue of their
ease of procurement [58–60], solid tissue biopsies are considered
the gold standard for diagnosis of human patients, allowing a
detailed tissue architectural classification of lymphoma subtypes
[1,2]. Recent years have seen an increasing recognition of the
diagnostic and prognostic value of histopathological subtypes of
lymphoma in dogs [56,61,62], which generally show remarkable
similarity to those of human patients [51,55,63].
Most of the dogs in this study were treated with a CHOP
protocol, considered to be the standard of care in the treatment of
canine lymphoma [64,65]; anti-canine CD20 mAbs similar to
rituximab are not currently available, precluding R-CHOP. A
proportion of the dogs had received at least one of the drugs on at
least one occasion within three weeks of sampling for this study,
prompting concern that such ‘pre-treatment’ might influence their
immune cell profile. In particular, we were concerned that prior
use of corticosteroids or cyclophosphamide would alter Treg
frequencies, given the known impact of these drugs on peripheral
T cells in rodents [66–68], humans [69–71] and dogs [72].
However, neither the cellular phenotype nor the prognosis of the
pre-treated dogs was significantly different from that of the
treatment-naı¨ve patients, presumably because such drugs were
administered on a limited number of occasions prior to sampling
and would thus have had only minimal opportunity to impact the
immune system. Recent studies of human patients receiving short-
term glucocorticoid therapy have similarly shown no change in the
frequency of peripheral Tregs [73,74]. In view of the lack of
impact of pre-treatment on these variables, all dogs of the
respective B and T cell groups were considered together in our
final analysis.
The impact of a number of clinical and immunophenotypic
variables on TTR, PFS and OS of dogs with multicentric
lymphoma was examined in the current study, including B or T
cell phenotype, age, sex, neutering status, bodyweight, body
condition, stage, substage, presence of hypercalcemia, treatment
protocol (CHOP versus ‘Other’) and the administration of rescue
therapy. Other than the predictable impact of rescue therapy on
OS, multivariable analysis revealed that age was the only factor
with an independent impact on prognosis, younger dogs enjoying
longer PFS. This has been a finding in other canine studies [62]
and also reflects the situation in human NHL, for which the
prognosis is worse in elderly patients [75,76]. The pathophysio-
logical basis of this observation remains unclear, but is thought to
reflect the generally poorer cellular repair mechanisms, progres-
sive immunosenescence, propensity for chemoresistant molecular
subtypes of DLBCL, and increased spectrum of comorbidities that
occur with advancing age [77].
p= 0.00005), gated CD5+ cells (C, showing the resident T cells; p = 0.41), or sequentially gated CD5+ and then CD4+ T cells (D, showing specifically the
resident CD4+ T cells; p = 0.74). Representative dot plots are shown for each of the groups, followed by box-and-whisker plots summarising the data.
In each of the dot plots, the respective isotype control stain is shown above the specific stain. In this and subsequent figures, red symbols correspond
to data from dogs ‘pre-treated’ with corticosteroids or any chemotherapeutic drug within three weeks of sampling. In the case of RH cases, square
symbols (%) represent data from dogs with dermatitis; diamonds (e) represent data from dogs with distant neoplasia; triangles (D) represent data
from dogs with immune-mediated disease; and inverted triangles (.) represent data from dogs with systemic infection. The expression of FOXP3 by
PBMCs (E; p = 0.21) or by the CD5+ (F; p = 0.53) or specific CD5+CD4+ (G; p = 0.15) T cells within PBMCs similarly showed no differences between
groups.
doi:10.1371/journal.pone.0105027.g002
Figure 3. Canine T cell lymphoma is associated with high-frequency Helios expression. Helios expression by cells harvested by fine needle
aspiration from the lymph nodes of dogs with B cell lymphoma (BCL), T cell lymphoma (TCL), reactive hyperplasia (RH) and mast cell tumors (MCT)
was examined as a marker for thymic Tregs, but the unexpectedly high frequency of Helios+ events in a few B cell and several T cell lymphoma cases
suggested neoplastic expression of this marker. Median frequency of Helios expression was significantly different between the groups (p = 0.00003).
Representative dot plots for BCL and TCL cases, with their respective isotype control stains, is shown (A), followed by box-and-whisker plots
summarising the data (B). (For key to symbols, refer to Figure 2).
doi:10.1371/journal.pone.0105027.g003
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Figure 4. Canine B cell lymphoma shows no deficit of cytotoxic T cells relative to thymic Tregs. When expressed as a proportion of all
cells aspirated from the lymph node, the frequency of CD8+ T cells (A,B) was decreased in BCL (and MCT), again attributed to neoplastic effacement
(p = 0.0005). The frequency of CD8+ cells within the CD5+ T cell population also showed differences between groups (C; p = 0.04). The ratio of
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Prognostic factors in other canine studies of multicentric
lymphoma have included sex [78,79], B or T immunophenotype
[53,80–82], stage [81,83–85], substage [79,83], serum calcium
concentration [86], packed cell volume [87], monocyte concen-
tration [88], prior administration of corticosteroids [89,90],
treatment protocol [62,91], coagulation profile [92], presence of
minimal residual disease after treatment [93], and cytomorpho-
logical and histopathological characteristics [56,61,62,81]. How-
ever, in common with our own observations, different studies have
yielded different conclusions and have not all been able to
demonstrate a prognostic impact of every one of the examined
variables: factors such as the number and clinical heterogeneity of
recruited patients and the nature of the specific end points
examined influence the results of such outcome analyses [94].
CD8+:FOXP3+ cells (D) was not significantly different between groups (p = 0.06), though dogs with BCL showed the six highest ratios of the cohort,
and a trend for higher values in the BCL group was observed. Indeed, the ratio of CD8+:FOXP3+Helios+ cells (E) was higher in the BCL than RH cases
(p = 0.04); only two data points for the MCT (3.48; 3.95) were available for this variable and were not therefore represented. Representative dot plots
for all the groups are shown alongside their respective isotype controls, followed by box-and-whisker plots summarising the data. (For key to
symbols, refer to Figure 2).
doi:10.1371/journal.pone.0105027.g004
Figure 5. Expression of T cell FOXP3 and Helios, and tumor cell MHC class II, all impact prognosis in dogs with B cell lymphoma. The
frequency of FOXP3+ cells within the ‘All’ gate (A), or within a cascaded AllRCD5+RCD4+ gate (B), influenced survival times. Overall survival times
were shorter in those dogs with frequencies of FOXP3+ T cells higher than the median value (A: p = 0.02); a similar pattern in progression-free survival
(PFS) was observed (B: p = 0.01). The frequency of Helios+ cells within the ‘All’ gate also influenced PFS (C: p = 0.01). The intensity of MHC class II
expression by the lymphoma cells, expressed as the ratio of geometric mean fluorescence intensity of MHC II+:MHC II2 cells within the CD52 subset
of the ‘All’ gate, was also of prognostic significance: time to remission was longer in those cases with less MHC class II expression per cell (D: p = 0.02).
doi:10.1371/journal.pone.0105027.g005
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More recent studies have stratified canine BCL patients by gene
profiling, demonstrating that in common with human DLBCL two
subtypes with different survival times – the germinal center B cell-
like and the activated B cell-like – can be distinguished, the latter
associated with a poorer prognosis [14,15]. While the individual
genes were different between the species, the general pathways
characterizing these subtypes were strikingly similar [14].
We used a cross-reactive mAb against murine Foxp3, validated
for use in dogs [46,95], to identify Tregs in this study. While a
large number of markers for Tregs have been proposed, FOXP3
remains the single most widely applied phenotypic credential of
regulatory activity in cancer and other studies [96–98], despite
being transiently expressed in activated human and canine
conventional T cells lacking regulatory function [46,99]. Com-
parisons of respective FOXP3+ and CD8+ cells between the study
groups yielded the initially surprising observation that dogs with
lymphoma had lower frequencies of these cells than those with RH
and MCTs. While FNAs of lymph nodes only ever approximate
the cellular content of the node, a consistent aspiration technique
was applied between patients and we could not attribute these
differences to trivial anomalies in the cellular harvest of
lymphomatous lymph nodes, which readily exfoliate cells. Rather,
we attributed this observation to cellular effacement of the normal
lymphoid tissue by neoplastic B or T cells.
The expression pattern of Helios was also unanticipated.
Applied as a marker of thymic Tregs in our study [100], the high
frequency of its expression in a number of TCL and two BCL
cases suggested that neoplastic lymphocytes may also express this
transcription factor, especially those of T cell origin. This
intriguing observation accords with similar findings in human
TCL, in which over-expression of non-DNA-binding, dominant
negative isoforms of Helios is thought to be involved in disease
progression [101]. Indeed, transgenic expression of short Helios
isoforms in mice promotes the development of TCL [102], while
ectopic expression of full-length Helios in B cells promotes BCL
[103], suggesting a potential pathogenic role in both immuno-
phenotypes. It is tempting to speculate that deregulated expression
of Helios may also be implicated in a minority of BCLs and some
TCLs in dogs. Insufficient data were available to allow survival
analysis of the Helioshigh group, but this could be a rewarding
avenue for future research; furthermore, immunocytochemical
staining could be employed to confirm expression of Helios by the
malignant T cells. In the light of these observations, Helios was
used as a surrogate marker for thymic Tregs only in the BCL dogs.
Review of the initial flow cytometric data prompted us to adopt
a cascaded gating approach in subsequent analysis of the BCL
cases, in which sequential CD5+ and CD4+ gates were applied to
identify the resident T cells. By ‘normalizing’ the data in this
manner, we endeavored to remove the dilutional influence of the
neoplastic B cells. We found no significant difference in the
frequency of FOXP3+ cells between the BCL and two control
groups, when expressed either as a proportion of CD5+ or of
CD5+CD4+ T cells. This observation contrasts with both a
comparison of the cellular phenotype of lymph nodes in human
patients with Hodgkin lymphoma and RH [104], and a recent
study by Mitchell et al, who examined the cytotoxic T cell
response in dogs with multicentric BCL treated with doxorubicin:
the mean initial frequency of Tregs was approximately four-fold
higher in Mitchell’s study than in ours [105]. While this disparity is
difficult to explain given the commonality of the species and
disease, there were some notable differences between the studies.
Thus, Mitchell et al harvested excisional biopsies, which represent
a more accurate sampling technique than FNAs, but recruited
only five dogs with BCL in total. We speculate that the five dogs
included in their study represented a Treghigh phenotype,
reminiscent of the highest-expressing patients in our own work,
but that the pattern of expression is generally more heterogeneous
among all dogs with BCL. Furthermore, for ethical and legal
reasons we were unable to sample the lymph nodes of healthy
animals; our comparisons were thus restricted to dogs with non-
neoplastic lymphadenomegaly and infiltration of the lymph nodes
by another round cell tumor, both of which could have harbored
higher frequencies of Tregs than healthy dogs. Indeed, this notion
of non-malignant expansion of Tregs reconciles with the known
activation of these cells in the context of inflammatory microen-
vironments [106].
Among the populations of cytotoxic cells within a tumor, CD8+
T cells play a prominent role in the elimination of neoplastic cells
[107]. Conventional wisdom places them on the other side of a
balancing act with Tregs and additional regulatory cells in solid
cancers [108]. We thus explored the possibility of a perturbation of
the relative frequencies of CD8+ and FOXP3+ T cells in BCL, but
found no evidence of a deficit of the former when compared to the
control groups. Rather, the ratio of CD8+ to regulatory T cells
tended to be higher in the lymph nodes of the BCL than RH dogs,
especially when thymic Tregs were identified by means of Helios
expression. While Helios has been criticized as a marker for
thymic Tregs [109], it is still generally regarded to be a valid
surrogate for this population of regulatory cells [110]. Future
studies could also examine the cross-reactivity of available mAbs
against neuropilin-1, considered by some to be a superior marker
[111] and implicated in Treg-mediated suppression within certain
Table 3. FOXP3, MHC class II, age at presentation and rescue therapy are independent prognostic factors in canine B cell
lymphoma.
Outcome metric Variable Median ratio Hazard ratio (95% CI) p value
TTR MHC class II 0.45 2.44 (1.36–4.35) 0.003
PFS Age 0.43 1.02 (1.01–1.04) 0.007
FOXP3+ (% CD5+CD4+) 0.29 1.10 (1.02–1.18) 0.01
OS Rescue therapy 0.54 0.29 (0.09–0.90) 0.03
FOXP3+ (%) 0.52 1.61 (1.11–2.32) 0.01
Abbreviations: TTR, time to remission; PFS, progression-free survival; OS, overall survival; CI, confidence interval; FOXP3+ (% CD5+CD4+), frequency of FOXP3+ cells within
the sequential CD5+ and CD4+ gates; FOXP3+ (%), frequency of FOXP3+ cells within the total harvested population; median ratio = ratio of median remission or survival
time (TTR/PFS/OS) of the sub-group of dogs with a value of the variable greater than the median of the group to that of the sub-group of dogs with a value of the
variable less than or equal to the median of the group.
doi:10.1371/journal.pone.0105027.t003
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cancer microenvironments [112]. Taken together, these data
provided no support for a gross numerical deficit of CD8+ T cells
in canine BCL, but further work will be required to explore
possible functional deficits of these critical cells.
Despite the lack of a significant difference in overall T cell
FOXP3 expression between the BCL and control groups, FOXP3
nevertheless emerged as an independent negative prognostic factor
in this study. This apparent paradox was likely to reflect the very
different microenvironments of B cell neoplasia and lymphoid
hyperplasia and the role of Tregs within them: in the context of
cancer, Tregs have traditionally been viewed as having a
pathogenic influence [22,23,42], co-opted by the cancer to help
thwart anti-neoplastic immune responses [113], while in the
context of RH, Tregs are likely to serve a beneficial role by
limiting over-exuberant inflammatory responses and collateral
tissue damage, adapting their suppressive program to the
prevailing milieu [106]. While our data reconciled with this view
of Tregs as being ‘bad’ in the context of canine BCL, aligning with
a plethora of studies of solid tissue cancers in humans and other
species [22,23,42] and some studies of human NHL [27–31], it
was at odds with a proportion of studies of human lymphoma that
have suggested the exact opposite – that Tregs are actually part of
the anti-neoplastic defenses [32–40], presumably because they are
able to draw on their armamentarium of suppressive mechanisms
to neutralize or kill neoplastic T and B cells, as well as a host of
innate immune cells subverted by the lymphoma. The bewildering
complexity of the microenvironment in both solid tissue and
hemolymphatic tumors is only now beginning to be elucidated
[16–20] and we speculate that Tregs may have divergent and
dynamic roles in this context that are predicated on both micro-
anatomical and temporal factors. Whether FOXP3+ Tregs play a
negative prognostic role in all canine BCL subtypes remains to be
determined, but they appeared to be deleterious in the context of
the cohort of dogs we examined. High Helios and low MHC II
expression were also of prognostic significance in this study. We
suggest that the Helios result reflects its predominant co-
localization with FOXP3 in thymic Tregs, while the MHC II
result reconciles with studies of both human [114–116] and canine
[117] BCL patients, in which low-level expression of this molecule
is thought to compromise the activation of T cell responses against
the neoplastic B cells and thus shorten survival. Interestingly, the
current study revealed an impact of MHC II expression on TTR
alone, but differences in patients and study design were likely to
account for this discrepancy from existing publications.
In common with all clinical research of an exploratory nature,
this study suffered a number of limitations. Staging was not
complete in every case and our end-point variables (TTR, PFS
and OS) were defined by owners’ and attending veterinarians’
observations of clinical signs and lymph node size. While diligent
follow-up of cases was undertaken, the pragmatic nature of clinical
veterinary practice meant that these values were likely to be best
estimates only. Furthermore, the cohort of BCL patients examined
was uncontrolled and relatively small, incorporating a number of
different treatment regimens. We chose not to censor dogs that
had received rescue therapy, instead incorporating them in the
analysis of OS to maximize power. Nevertheless, despite the
heterogeneity of the cohort, we were able to demonstrate that
frequency of FOXP3 expression was an independent prognostic
factor. Future studies of carefully stratified canine lymphoma
patients treated with the same chemotherapy protocol are planned
to confirm the results of the current work, which must be
considered preliminary until they are prospectively validated in
this manner.
In summary, we have presented evidence suggesting that
FOXP3+ Tregs have a negative prognostic impact in canine
multicentric BCL. We suggest that dogs with BCL, in common
with human NHL patients, harbor a spectrum of interacting
regulatory cells within the neoplastic lymph nodes, including
thymic Tregs. We present further evidence of similarities between
canine BCL and human NHL, thus helping to vindicate this large
animal model of lymphoid cancer. There is an increasing need to
find new ways of modulating the immune system as an integral
part of multimodal veterinary cancer therapy. Regulatory T cells
are an obvious candidate in such therapeutic endeavors, since this
work suggests that they play a decisive role in the pathogenesis of
canine BCL.
Supporting Information
Figure S1 Cytological characteristics of representative
B cell lymphoma, T cell lymphoma, reactive hyperplasia
and mast cell tumor cases. Smears of fine needle aspirates
were stained with modified Wright’s stain and examined by a
board-certified clinical pathologist in each case to reach a
cytological diagnosis. A representative image of each group is
presented (100x oil immersion lens; bar = 10 mm). (A) Diffuse large
B cell lymphoma (DLBCL), characterized by a dominance of
medium-to-large lymphocytes with immature chromatin and
prominent nucleoli. (B) Peripheral T cell lymphoma (PTCL),
characterized by a dominance of medium-to-large lymphocytes
with eccentric and occasionally indented nuclei, smooth chromatin
and multiple nucleoli. (C) Reactive hyperplasia (RH), character-
ized by a mixed population of lymphocytes with predominance of
small lymphocytes, and increased numbers of medium-to-large
lymphocytes, plasma cells and Mott cells. (D) Draining lymph
node of a mast cell tumor (MCT), characterized by numerous
moderately-to-well granulated mast cells, occasional eosinophils
and a mixed lymphocyte population, consistent with a metastatic
mast cell tumor.
(TIF)
Figure S2 Younger dogs, those treated with CHOP and
those ‘rescued’ show longer survival in B cell lympho-
ma. (A) Dogs with B cell lymphoma that were less than or equal to
the median age of the group (112 months) had longer progression-
free survival (PFS: median 174 vs 74 days; median ratio = 0.43,
p = 0.006) but not overall survival (OS, p = 0.11; data not shown);
time to remission (TTR) was also no different between younger
and older dogs (p = 0.57; data not shown). The significance of age
on PFS remained in the multivariable regression model,
demonstrating that it was an independent prognostic factor in
this cohort of dogs. (B) CHOP chemotherapy was associated with
longer PFS than the other treatments in the BCL group (CHOP,
median 175 days; Other [including COP (n = 3), cytarabine, L-
asparaginase, lomustine (n = 3) and prednisolone alone (n = 1)],
median 45 days; p = 0.01). However, when interrogated in
multivariable analysis, the variable ‘protocol’ no longer remained
significant after accounting for age, reflecting the younger mean
age of dogs treated with CHOP than ‘Other’ protocols (93 versus
123 months; p = 0.05). (C) Dogs receiving rescue therapy had
longer OS (median 322 days) than those not receiving rescue
therapy (174 days, median ratio 0.54; p = 0.049).
(TIF)
Table S1 Cytomorphological criteria for the assess-
ment of lymphoma cases.
(DOC)
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Table S2 Signalment, therapy and immunophenotype
of B cell lymphoma dogs. Abbreviations: mo, months; m,
male; f, female; n, neutered; e, entire; ND, not determined;
chemotherapy agents: CHOP, protocol in which cyclophospha-
mide (C), doxorubicin (H), vincristine (O) and prednisolone (P) are
administered; COP, protocol in which cyclophosphamide (C),
vincristine (O) and prednisolone (P) are administered; L,
lomustine; Cy, cytosine arabinoside; Ap, L-asparaginase; Chl,
chlorambucil; VCAA, protocol in which vincristine (V), cyclo-
phosphamide (C), L-asparaginase (A) and doxorubicin (A) are
administered; LMP, protocol in which chlorambucil (L), metho-
trexate (M) and prednisolone (P) are administered; DMAC,
protocol in which dexamethasone (D), melphelan (M), actinomy-
cin-D (A) and cytosine arabinoside (C) are administered; Ma,
masitinib; Vb, vinblastine; Pr, procarbazine; -, no rescue therapy
administered (Rescue therapy) or remission not achieved (TTR); +,
no progression (PFS) or alive at conclusion of study (OS) and
therefore censored from survival analysis. Notes: The immunophe-
notype lists the per cent positive staining for the listed antigen; 1:
these cases were classified as B cell lymphomas with aberrant CD5
expression.
(DOC)
Table S3 Signalment, therapy and immunophenotype
of T cell lymphoma dogs. Abbreviations: mo, months; m,
male; f, female; n, neutered; e, entire; ND, not determined;
chemotherapy agents: see Table S2 and Dex, dexamethasone; -,
no rescue therapy administered (Rescue therapy) or remission not
achieved (TTR); +, no progression (PFS) or alive at conclusion of
study (OS) and therefore censored from survival analysis. Notes:
The immunophenotype lists the per cent positive staining for the
listed antigen.
(DOC)
Table S4 Disease subtype and signalment of reactive
hyperplasia dogs. Abbreviations: mo, months; m, male; f,
female; n, neutered; e, entire.
(DOC)
Table S5 Signalment of mast cell tumor dogs. Abbrevi-
ations: mo, months; f, female; n, neutered; e, entire.
(DOC)
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